After quite a crushing bull stampede in 2024, the stock price of weight loss drug star Novo Nordisk (NYSE ... the U.S. -- obesity affected more than 1 billion people worldwide in 2022.

Type 1 diabetes occurs when the immune system attacks pancreatic beta cells. Type 2 diabetes happens when the body cannot use insulin effectively. The two types differ in symptoms, causes ...

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much longer. Hims & Hers Health Inc.’s stock plunged last week when the ...

Novo acquired ocedurenone in October 2023 in an up to $1.3 billion deal. By the following fall, however, Novo trashed the asset after the drug failed to improve systolic blood pressure in a phase ...

from KBP Biosciences for up to $1.3 billion. However, in June 2024 Novo Nordisk said it was recognising a loss of around 5.7 billion Danish crowns ($800 million) in relation to the drug after ...

Merilog’s approval comes as the insulin space has over the past year suffered several setbacks, including strong calls for price caps and, potentially, the rise of the mammoth GLP-1 market ... In ...

Novo Nordisk is by far the leader in the GLP-1 drug market. The company's pipeline in this area is also very deep. The Danish drugmaker is also looking to diversify its lineup. Novo Nordisk's work ...

Subscribe Login Register Log out My Profile Subscriber Services Search PGe NEWSLETTERS PG STORE ARCHIVES OBITUARIES JOBS PUBLIC NOTICES REAL ESTATE CLASSIFIEDS EVENTS PETS CONTACT US ADVERTISING ...

Obesity drugmakers Eli Lilly (NYSE:LLY) and Novo Nordisk (NVO ... Hers Health (HIMS), which offer cheaper versions of its GLP-1 product semaglutide, capitalizing on a regulatory loophole amid ...

He was 84. The director of more than 20 films, including “Xica da Silva” and “Bye Bye Brazil,” Diegues was a leading figure in Cinema Novo, a movement that emerged in the 1960s and used film to ...

(Bloomberg) -- Novo Nordisk A/S shares are on track for their ... compounded versions of the class of medicines known as GLP-1 drugs. But drugmakers are pushing back, on the basis that compounded ...